|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alberg AJ, Brock MV, Ford JG, Samet JM and
Spivack SD: Epidemiology of lung cancer: Diagnosis and management
of lung cancer, 3rd ed: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest. 143 Suppl
5:e1–e29. 2013. View Article : Google Scholar
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hasanbasic I, Cuerquis J, Varnum B and
Blostein MD: Intracellular signaling pathways involved in
Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart
Circ Physiol. 287:H1207–H1213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee WP, Wen Y, Varnum B and Hung MC: Akt
is required for Axl-Gas6 signaling to protect cells from
E1A-mediated apoptosis. Oncogene. 21:329–336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vajkoczy P, Knyazev P, Kunkel A, Capelle
HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U,
Essig M, Read TA, et al: Dominant-negative inhibition of the Axl
receptor tyrosine kinase suppresses brain tumor cell growth and
invasion and prolongs survival. Proc Natl Acad Sci USA. 103:pp.
5799–5804. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lay JD, Hong CC, Huang JS, Yang YY, Pao
CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, et al: Sulfasalazine
suppresses drug resistance and invasiveness of lung adenocarcinoma
cells expressing AXL. Cancer Res. 67:3878–3887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Linger RM, Keating AK, Earp HS and Graham
DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel
therapeutic targets in solid tumors. Expert Opin Ther Targets.
14:1073–1090. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hutterer M, Knyazev P, Abate A, Reschke M,
Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, et
al: Axl and growth arrest-specific gene 6 are frequently
overexpressed in human gliomas and predict poor prognosis in
patients with glioblastoma multiforme. Clin Cancer Res. 14:130–138.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meric F, Lee WP, Sahin A, Zhang H, Kung HJ
and Hung MC: Expression profile of tyrosine kinases in breast
cancer. Clin Cancer Res. 8:361–367. 2002.PubMed/NCBI
|
|
13
|
Shieh YS, Lai CY, Kao YR, Shiah SG, Chu
YW, Lee HS and Wu CW: Expression of axl in lung adenocarcinoma and
correlation with tumor progression. Neoplasia. 7:1058–1064. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo
SS, Lui WY and Lin WC: Clinical significance of AXL kinase family
in gastric cancer. Anticancer Res. 22:1071–1078. 2002.PubMed/NCBI
|
|
15
|
Byers LA, Diao L, Wang J, Saintigny P,
Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An
epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a
therapeutic target for overcoming EGFR inhibitor resistance. Clin
Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th. Springer;
New York, NY: 2010
|
|
20
|
Nagai Y, Miyazawa H, Huqun, Tanaka T,
Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M,
et al: Genetic heterogeneity of the epidermal growth factor
receptor in non-small cell lung cancer cell lines revealed by a
rapid and sensitive detection system, the peptide nucleic
acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McCarty KS Jr, Miller LS, Cox EB, Konrath
J and McCarty KS Sr: Estrogen receptor analyses. Correlation of
biochemical and immunohistochemical methods using monoclonal
antireceptor antibodies. Arch Pathol Lab Med. 109:716–721.
1985.PubMed/NCBI
|
|
22
|
Hirano H, Maeda H, Takeuchi Y, Susaki Y,
Kobayashi R, Hayashi A, Ose N, Yamaguchi T, Yokota S and Mori M:
Lymphatic invasion of micropapillary cancer cells is associated
with a poor prognosis of pathological stage IA lung
adenocarcinomas. Oncol Lett. 8:1107–1111. 2014.PubMed/NCBI
|
|
23
|
Shimokawa T, Seike M, Soeno C, Uesaka H,
Miyanaga A, Mizutani H, Kitamura K, Minegishi Y, Noro R, Okano T,
et al: Enzastaurin has anti-tumour effects in lung cancers with
overexpressed JAK pathway molecules. Br J Cancer. 106:867–875.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:pp.
12085–12090. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishikawa M, Sonobe M, Nakayama E,
Kobayashi M, Kikuchi R, Kitamura J, Imamura N and Date H: Higher
expression of receptor tyrosine kinase Axl, and differential
expression of its ligand, Gas6, predict poor survival in lung
adenocarcinoma patients. Ann Surg Oncol. 20 Suppl 3:S467–S476.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilson C, Ye X, Pham T, Lin E, Chan S,
McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, et al: AXL
inhibition sensitizes mesenchymal cancer cells to antimitotic
drugs. Cancer Res. 74:5878–5890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:pp. 1124–1129. 2010;
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reichl P, Dengler M, van Zijl F, Huber H,
Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M,
Grubinger M and Mikulits W: Axl activates autocrine transforming
growth factor-β signaling in hepatocellular carcinoma. Hepatology.
61:930–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu F, Li J, Jang C, Wang J and Xiong J:
The role of Axl in drug resistance and epithelial-to-mesenchymal
transition of non-small cell lung carcinoma. Int J Clin Exp Pathol.
7:6653–6661. 2014.PubMed/NCBI
|
|
31
|
Debruyne DN, Bhatnagar N, Sharma B, Luther
W, Moore NF, Cheung NK, Gray NS and George RE: ALK inhibitor
resistance in ALK-driven neuroblastoma is associated with AXL
activation and induction of EMT. Oncogene. 35:3681–3691. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Asamura H, Goya T, Koshiishi Y, Sohara Y,
Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, et
al: Japanese Joint Committee of Lung Cancer Registry: A Japanese
Lung Cancer Registry study: Prognosis of 13,010 resected lung
cancers. J Thorac Oncol. 3:46–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grossi F, Dal Bello MG, Salvi S, Puzone R,
Pfeffer U, Fontana V, Alama A, Rijavec E, Barletta G, Genova C, et
al: Expression of ribonucleotide reductase subunit-2 and
thymidylate synthase correlates with poor prognosis in patients
with resected stages I–III non-small cell lung cancer. Dis Markers.
2015:3026492015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng Z, Chen T, Li X, Haura E, Sharma A
and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung
cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mascaux C, Martin B, Paesmans M, Berghmans
T, Dusart M, Haller A, Lothaire P, Meert AP, Lafitte JJ and Sculier
JP: Has Cox-2 a prognostic role in non-small-cell lung cancer? A
systematic review of the literature with meta-analysis of the
survival results. Br J Cancer. 95:139–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Noro R, Honda K, Tsuta K, Ishii G,
Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, et
al: Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell
motility gene amplification. Ann Oncol. 24:2594–2600. 2013.
View Article : Google Scholar : PubMed/NCBI
|
